Hims vs. Keeps: What’s Actually Different When the Drugs Are the Same?

The useful question with comparisons & decision-making is not whether one photo looks better or worse. It is whether the pattern, timing, measurements, and treatment trade-offs point to a decision that will still make sense six months from now.

A friend of mine, Ben, a 31-year-old software developer in Austin, texted me a screenshot last October. He’d pulled up Hims and Keeps side by side on his laptop, toggling between tabs like he was comparison-shopping for the same pair of sneakers on two different sites. “I literally cannot tell the difference,” he wrote. “Am I missing something?” He wasn’t, really. And that confusion is the whole story.

Hims and Keeps are two direct-to-consumer telehealth services that prescribe finasteride and minoxidil for pattern hair loss. The active ingredients are identical. The FDA-approved doses are identical. The differences come down to pricing tiers, formulation options (topical combos, oral combos, branded packaging), and the customer experience wrapper around the same two drugs. Understanding which one suits you better requires understanding what you’re actually treating, what the drugs do, and what the real cost calculus looks like. That’s what this piece covers.

The Biology You Need Before You Compare Anything

Pattern hair loss has been formally studied since James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences, which established the relationship between androgens and male hair loss. Hamilton observed that men castrated before puberty simply did not develop the recession and crown thinning characteristic of androgenetic alopecia. O’Tar Norwood extended that work in a 1975 Southern Medical Journal paper, formalizing a seven-stage classification system (with variant subtypes, including the Type A pattern where loss moves front-to-back rather than starting at the temples and crown simultaneously). The combined Hamilton-Norwood scale has held up for over 70 years, largely because it’s simple enough to use reliably while capturing enough natural variation to be clinically useful.

The engine behind all of this is dihydrotestosterone (DHT), a potent androgen produced from testosterone by the enzyme 5-alpha reductase. In genetically susceptible follicles, DHT binds to the androgen receptor in the dermal papilla and triggers a cascade across successive growth cycles: shorter anagen (growth) phases, longer telogen (resting) phases, and physical shrinkage of the dermal papilla itself. Hair goes from thick terminal strands to thin, short, eventually nonpigmented vellus wisps. That’s follicular miniaturization.

The genetics are polygenic. The androgen receptor gene sits on the X chromosome, which is why your maternal grandfather gets referenced as a predictor. But the paternal side and other autosomal loci contribute meaningfully, so using grandpa as a crystal ball is imprecise at best.

The two drugs that exploit this biology: finasteride inhibits type II 5-alpha reductase, lowering scalp DHT. Dutasteride (used off-label for hair loss) inhibits both type I and type II isoforms, lowering DHT more aggressively, with corresponding improvements in clinical trials. And then there’s minoxidil, which works through a different, still not fully understood mechanism involving potassium channel opening, vasodilation, and direct effects on follicle cycling.

What Dermatologists Actually Do (That Telehealth Can’t Replicate Fully)

The American Academy of Dermatology’s clinical guidelines for hair loss call for a structured evaluation: patient history, family history, scalp examination, trichoscopy (dermoscopy of the scalp), and selective labs.

Trichoscopy is where the resolution gap matters. In androgenetic alopecia, characteristic findings include hair shaft diameter variability (caliber variability of 20% or more), yellow dots from empty follicular ostia, and decreased follicular unit density in affected zones with preservation of the occipital donor area. You’re not picking that up from a selfie.

Labs are selective, not routine. Ferritin, TSH, vitamin D, and CBC make sense when telogen effluvium is suspected or when thinning is diffuse. The AAD doesn’t recommend androgen panels routinely in men with classic pattern loss because the diagnosis is clinical.

Standardized photography (front, top, sides, back, consistent distance and lighting) is surprisingly important for tracking. Hair loss is slow enough that your own mirror perception adapts. Photos don’t lie.

Both Hims and Keeps use asynchronous telehealth consultations, which are adequate for straightforward pattern loss. But telehealth cannot replace trichoscopy or biopsy. For anyone with patchy loss, scalp pain or burning, scarring, or rapid progression (more than one Norwood stage per year), an in-person dermatology visit is non-negotiable.

The Treatment Menu: Same Drugs, Different Wrappers

Here’s the boring truth about Hims vs. Keeps: the clinical options overlap almost completely.

Oral finasteride 1 mg daily has the largest evidence base. The original five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 showed sustained improvements in hair count and patient self-assessment versus placebo. Sexual dysfunction, the side effect everyone Googles, affects a small percentage of users in randomized trials and is generally reversible on discontinuation. Both services prescribe it. Both charge roughly the same for generic.

Topical minoxidil 5% is FDA-approved for over-the-counter use. Response typically becomes visible at three to six months, with roughly 40 to 60 percent of users showing meaningful improvement in randomized trials. A subset of patients lack the sulfotransferase enzyme activity needed to convert minoxidil to its active form, which partly explains nonresponse. Again, available through both services.

Low-dose oral minoxidil (0.25 to 5 mg daily) is increasingly used off-label after Vañó-Galván et al.’s 2021 multicenter study of 1,404 patients documented efficacy at lower doses than the original cardiovascular formulation. The side-effect profile at low doses is more manageable than the drug’s hypertension-era reputation suggests, though periorbital edema and hypertrichosis do occur. Some telehealth platforms now offer this; availability varies.

Dutasteride produces larger DHT reductions and larger hair density improvements in head-to-head trials versus finasteride (Olsen et al., 2006), but it’s off-label for hair loss and less commonly prescribed through DTC platforms.

Platelet-rich plasma (PRP) and microneedling have a modest evidence base as adjuncts (Gentile & Garcovich, 2020, International Journal of Molecular Sciences; several smaller JAMA Dermatology trials). Reasonable add-ons, not replacements.

Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles from donor to recipient sites. It’s appropriate when loss is stable, donor capacity is adequate, and expectations are realistic.

If you’re weighing Hims against Keeps, or either against a local dermatologist’s prescription plus a GoodRx coupon, the core tool for comparisons & decision-making is understanding where you sit on the staging spectrum and which formulations actually match your stage.

The Real Cost Breakdown

This is where the differentiation between services gets tangible, even if it’s not dramatic.

Generic oral finasteride 1 mg runs $10 to $25 per month at US pharmacies with discount cards, and as low as $5 to $15 monthly through DTC telehealth. Branded Propecia still costs $70 to $90 monthly, with zero documented clinical advantage. That markup is paying for a brand name and nothing else.

Generic topical minoxidil 5% costs $10 to $30 per month. Branded Rogaine roughly doubles that. Foam and solution are clinically equivalent; foam gets a slight nod from patients who report scalp irritation with the solution’s propylene glycol vehicle.

Low-dose oral minoxidil in generic form is often under $15 monthly. The cost driver is the prescribing visit ($50 to $150 through telehealth, or potentially covered by insurance through a dermatology appointment).

Hair transplantation in the US typically runs $4 to $10 per graft for FUE. A typical 2,500 to 3,500 graft case lands at $10,000 to $35,000. Turkish clinics offer $2,000 to $5,000 for similar graft counts, reflecting labor cost and overhead differences (not necessarily quality differences, though the variance is wide).

PRP runs $500 to $1,500 per session, with most protocols calling for three to four sessions the first year plus maintenance. First-year PRP cost can exceed an entire year of combination medical therapy.

Insurance generally doesn’t cover pattern hair loss treatment (classified as cosmetic). HSAs and FSAs may cover prescribed medications and physician visits but typically not surgical procedures.

My honest take: for most men with early to moderate pattern loss, the monthly drug cost is trivially low. The real cost is the years lost to indecision. Finasteride at $12 a month started at Norwood 2 is dramatically more effective than finasteride at $12 a month started at Norwood 5. The drug didn’t get worse. The follicles just weren’t there anymore.

Lifestyle Factors: What Moves the Needle and What Doesn’t

Think of pattern hair loss like a river current. Genetics determine the speed and direction. Lifestyle factors are the wind. Sometimes the wind matters; usually, the current wins.

Smoking accelerates loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus nonsmokers.

Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes via telogen effluvium. Repletion in deficient patients reduces shedding. Supplementation in iron-replete patients does nothing for density.

Vitamin D deficiency is more strongly associated with alopecia areata than androgenetic alopecia, but severe deficiency may contribute to overall hair fragility per JAAD reviews. Supplement if you’re actually deficient; don’t megadose hoping for regrowth.

Stress can trigger telogen effluvium two to three months after a severe acute event, typically resolving within six to nine months. It doesn’t cause androgenetic alopecia directly, but it can unmask or accelerate it.

Anabolic steroid use accelerates pattern loss through supraphysiologic androgen exposure, with effects that may not fully reverse after discontinuation.

Diet quality matters at the margin. Severe caloric restriction, very low protein intake, and rapid weight loss reliably produce telogen effluvium. Modest dietary improvements don’t produce visible hair benefits beyond correcting specific deficiencies.

Sleep deprivation has been linked to elevated cortisol and altered circadian follicle regulation. The clinical magnitude in normal adults is small, but months of severely disrupted sleep may contribute to shedding.

When Telehealth Isn’t Enough

Sudden, diffuse shedding in the last six months? That’s likely telogen effluvium, not pattern loss. Needs workup, not a subscription.

Patchy, smooth, well-circumscribed bald spots? Alopecia areata. Different disease, different treatment.

Scalp pain, burning, redness, scaling, or visible scarring? Scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) demand prompt in-person diagnosis. Permanent follicle destruction is the risk (Kassira et al., JAAD, 2017).

Hair loss in women with menstrual irregularities, acne, or hirsutism? Endocrine evaluation for PCOS or other androgen excess.

Hair loss that fails to respond to 12 months of documented standard medical therapy? Reassessment.

The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for consultation. That’s a low bar, and it should be.

FAQs

What is shock loss after a hair transplant?

Shock loss is temporary shedding of native or transplanted hairs in the weeks following a transplant. It typically resolves over three to six months as follicles re-enter the growth phase.

Is oral minoxidil better than topical?

Low-dose oral minoxidil produces comparable effects to topical minoxidil with better adherence in many patients. The choice depends on side-effect tolerance and preference, and should be made with a prescribing clinician.

Does minoxidil work for everyone?

Minoxidil produces visible improvement in roughly 40 to 60 percent of users in randomized trials, with response emerging at three to six months. Some patients lack sufficient sulfotransferase activity for activation, partly explaining nonresponse.

How accurate are AI hair-loss assessment tools?

They provide reasonable orientation for self-screening but don’t replace dermatologic evaluation. Best used as a starting point for understanding likely stage and treatment options.

Can diet alone slow hair loss?

Diet can address contributing factors (iron deficiency, severe caloric restriction) but cannot stop the underlying genetic process of androgenetic alopecia.

Can stress cause permanent hair loss?

Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, though it can unmask or accelerate underlying pattern loss in susceptible individuals.

What’s the actual difference between Hims and Keeps?

The active medications and doses are the same. Differences are in subscription pricing, combination formulation options, and platform experience. Neither has a clinical advantage over the other for the core FDA-approved treatments.

References

1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
2. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
3. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
4. American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
5. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
6. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
7. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
8. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
9. Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
10. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.

Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.

Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.